G1/S-specific cyclin-E1 is a protein that in humans is encoded by the CCNE1 gene. [5] The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK.

2025年3月30日 · CCNE1 (Cyclin E1) is a Protein Coding gene. Diseases associated with CCNE1 include Pancreatic Cancer and Ovarian Cancer. Among its related pathways are Defective binding of RB1 mutants to E2F1, (E2F2, E2F3) and Autodegradation of the E3 ubiquitin ligase COP1.

2022年4月20日 · To uncover therapeutic targets for tumours with CCNE1 amplification, we undertook genome-scale CRISPR–Cas9-based synthetic lethality screens in cellular models of CCNE1 amplification.

6 天之前 · Ovarian cancers (OVCAs) and endometrial cancers (EMCAs) with CCNE1-amplification are often resistant to standard treatment and represent an unmet clinical need. Synthetic-lethal screening ...

2023年3月24日 · Our study demonstrated that CCNE1 is upregulated in multiple cancers in the TCGA database and may be a promising predictive biomarker for the immunotherapy response in some types of cancers. Moreover, CCNE1 knockdown can suppress the proliferation, migration and invasion of UCEC cells.

Here, we review the current understanding of one of the most common genetic alterations in epithelial ovarian cancer, CCNE1 (cyclin E1) amplification, and its role as a potential predictive marker of cytotoxic chemotherapy resistance.

2021年9月21日 · These studies demonstrate that CCNE1 CN is a clinically tractable biomarker predicting responsiveness to low-dose WEE1i-ATRi for aggressive subsets of OVCAs/EMCAs. Gynecological cancers can be heterogeneous in anatomic location, histology, and genomics.

2024年5月29日 · Recent studies suggest that CCNE1 amplification is a potential target for new synthetic lethality-based treatments, including CDK2-selective and PKMYT1 inhibition. This study explores the clinical and genomic characteristics of CCNE1 -amplified BCs.

2025年2月9日 · CCNE1 Is a Putative Therapeutic Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma. Cyclin E1 expression and malignancy in meningiomas. Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.

2025年2月9日 · Title: PKMYT1: A Potential Target for CCNE1 Amplificated Colorectal Tumors. Long noncoding RNA LINC02568 sequesters microRNA-874-3p to facilitate malignancy in breast cancer cells via cyclin E1 overexpression.

2016年10月18日 · CCNE1 is a predictive and immunotherapeutic indicator in various cancers including UCEC: a pan-cancer analysis. Zheng X, Chen L, Liu W, Zhao S, Yan Y, Zhao J, Tian W, Wang YZheng X, et al. Hereditas, 2023 Mar 24. PMID 36964635; Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.

A number of studies revealed that CCNE1 copy number amplification and overexpression (on mRNA or protein expression level) were associated with prognosis of diverse cancers, however, the results were inconsistent among studies.

2023年1月24日 · Background: Cyclin E1 (CCNE1) amplification (CCNE1 Amp) drives chromosomal instability (CIN) and is associated with immune cell exclusion, liver metastasis, therapeutic resistance, and poor survival in gastric adenocarcinoma (GA).

4 天之前 · BLU-222 is an investigational CDK2i with strong antitumor activity as monotherapy in preclinical CCNE1-amplified ovarian cancer models.Here, we identified additional biological determinants to predict BLU-222 monotherapy activity in CCNE1-high ovarian and endometrial cancers and demonstrated the use of expression of these biomarkers in predicting response …

2022年9月9日 · Cyclin E1 (CCNE1) is a protein-coding gene that belongs to the Cyclin family of genes which controls the G1/S phase transition of the cell cycle. Previously, its abnormal expression pattern has been examined and found to be …

2013年11月13日 · Cyclin-dependent kinase (CDK) activation requires association with cyclins (e.g., CCNE1) and phosphorylation by CAK (CCNH; 601953), and leads to cell proliferation. Inhibition of cellular proliferation occurs upon association of CDK inhibitor (e.g., CDKN1B; 600778) with a cyclin-CDK complex.

2020年5月5日 · Here, we review the current understanding of one of the most common genetic alterations in epithelial ovarian cancer, CCNE1 (cyclin E1) amplification, and its role as a potential predictive marker of cytotoxic chemotherapy resistance.

2023年2月2日 · Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification

CCNE1 Amplification is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CCNE1 Amplification and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [

In general, CCAT1 regulate the expression of CCNE1 by acting as a ceRNA to sponge miR-30c-2-3p in regulating the cell proliferation of HCC. These results suggest that CCAT1 may be a new therapy target for HCC in the future.